[{"orgOrder":0,"company":"35Pharma","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Large molecule","year":"2024","type":"Series C Financing","leadProduct":"HS135","moa":"","graph1":"Technology","graph2":"Approved","graph3":"35Pharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"35Pharma \/ Frazier Life Sciences","highestDevelopmentStatusID":"12","companyTruncated":"35Pharma \/ Frazier Life Sciences"}]

Find Clinical Drug Pipeline Developments & Deals by 35Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Duphat
                          Not Confirmed
                          Duphat
                          Not Confirmed

                          Details : The company plans to use the proceeds to advance its pipeline of Activin and GDF inhibitors, HS135 for pulmonary hypertension and HS235 for cardiometabolic disease and obesity.

                          Brand Name : HS135

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          November 26, 2024

                          Lead Product(s) : HS135

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Frazier Life Sciences

                          Deal Size : $53.0 million

                          Deal Type : Series C Financing

                          blank